Laboratorium Dr. Deppe Gmbh
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Laboratorium Dr. Deppe Gmbh - overview
Established
1980
Location
Kempen, -, Germany
Primary Industry
Consumer Products
About
Laboratorium Dr. Deppe GmbH specializes in tailored succession solutions for mid-sized enterprises, focusing on sustainable growth and development through strategic investments and partnerships. Founded in 1980 and headquartered in Kempen, Germany, Laboratorium Dr. Deppe GmbH offers specialized succession solutions for mid-sized enterprises.
The firm was acquired by Invision in August 2017, marking a strategic pivot to enhance corporate development. Hendrik Hahn and Mark Derks currently serve as the CEOs of the firm. Laboratorium Dr. Deppe GmbH provides tailored succession solutions that promote ongoing development and sustainable success for mid-sized enterprises.
The company enables management teams to assume ownership through financing solutions, facilitating the spin-off of corporate divisions to unlock value. Their services include strong partnerships aimed at sustainable corporate development, with a focus on companies in the DACH region (Germany, Switzerland, Austria) and neighboring countries, particularly those generating annual revenues between EUR 25 million and EUR 200 million. Laboratorium Dr. Deppe GmbH operates under a revenue model that emphasizes strategic investments and partnerships, focusing on equity stakes that align with clients' growth goals.
The firm engages in direct partnerships rather than subscription models, fostering collaboration with management teams to enhance operational effectiveness. While specific pricing plans are confidential, the firm’s approach centers on providing capital and strategic guidance, reinforcing its commitment to responsible investing. Laboratorium Dr. Deppe GmbH, through its parent company Invision, plans to leverage recent acquisitions for growth.
The firm aims to expand its market reach in the DACH region and explore opportunities in neighboring markets by utilizing resources gained from its last acquisition in August 2017. The emphasis will be on developing new tailored succession solutions to meet the evolving needs of mid-sized enterprises.
Current Investors
Invision
Primary Industry
Consumer Products
Sub Industries
Beauty & Hygiene
Website
https://www.invision.ch/
Verticals
Manufacturing
Company Stage
Mature - Buyout
Total Amount Raised
Subscriber access only
Laboratorium Dr. Deppe Gmbh - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Buyout | Completed | Laboratorium Dr. Deppe Gmbh | - |
Displaying 1 - 1 of 1
Laboratorium Dr. Deppe Gmbh - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.